Internet Drug
Pharmaceutical News & Information; Updated Daily

Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

4/27 Lack of Transparency Turns Out to Make a Lot of Money for PBMs
A Secret Profit Formula Loved by Drug Middlemen Is at Risk One reason that clients, including employers, unions, and insurance companies, may not understand what is going on is the complexity of the PBM contracts they sign.... They can contain multiple price guarantees for various types of drugs -- generic, brand, specialty -- as well as a separate list of guarantees for rebates .... Bloomberg

4/27 Supremes to Decide When 180-Day Notice Must Be Given for Biosimilars
U.S. top court grapples over making copycat biologics available sooner The nine justices heard arguments in an appeal by Novartis AG of a lower court decision that prevented the Swiss pharmaceutical company from selling its biosimilar version of California-based Amgen's $1-billion-a-year Neupogen until six months after the Food and Drug Administration approved it .... Reuters

4/27 Role of Biosimilars Hard Fought In Autoimmune Sector
Drugmakers battle for slice of Humira's billions Although approved in the U.S., the Humira and Enbrel biosimilars have been held up by patent disputes. To complicate matters, the already-approved biosimilars do not have interchangeability status, as their approvals predated the requirement. .... MM&M
See also: Top 25 autoimmune brands in 2016, based on U.S. sales

4/27 Ingrezza Pricing at $60K; Firms Says They've Been Talking with Payers for Months; States Will Wait 180 Days Before Covering
Neurocrine goes high — $60K-plus high — with price for new movement drug Ingrezza Neurocrine is also this year anticipating an FDA go-ahead for its 80 mg version, which it says it expects will be "priced substantially similar" to its 40 mg counterpart .... Fierce Pharma

4/27 Repatha Sales Grow, But Not As Strongly As Hoped. Enbrel Sales Fall 15%
New Cholesterol Drug Falls Short as Sales Driver for Amgen In the U.S. and Europe Repatha prescriptions grew 14 percent and 28 percent, respectively, from the fourth quarter .... Bloomberg

4/27 Generic for Vytorin Approved
Merck cholesterol drug Vytorin faces competition from Impax, Teva generics The FDA has approved Impax Laboratories's generic version of Vytorin, while Teva Pharmaceutical Industries launched its generic version of the drug in the United States. .... Bloomberg

4/27 "Fewer But Bigger Launches": GSK Head Leery of Research Flops
Glaxo's new CEO Walmsley to tighten R&D focus Glaxo's low research productivity is viewed as a fundamental problem by investors, who have been stung by some high-profile failures in recent years .... Marketwatch

4/27 Pain Tablets Formulated So They Can't Be Cut, Crushed, Dissolved, or Injected
FDA Approves RoxyBond Tablets, First Immediate-Release Opioid Analgesic With Abuse-Deterrent Label Claims The product is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or attempts at chemical extraction .... PTCommunity

4/27 Some Predictors of Success Found in Treatments for Panic Disorder
Researchers explore personalized pharmacotherapy to treat panic attacks The longer the treatment, the higher the rate of patients free from panic attacks at the endpoint of RCTs with venlafaxine XR .... Personalized Medicine in Psychiatry

4/27 Internet Drug News Fast Takes:
Colonoscopy prevented more than 50,000 deaths from CRC in the US over 3 years
Drugs firms call for phased transition of regulation after Brexit
'Exciting' blood test spots cancer a year early
Inexpensive Drug Prevents Deaths in New Mothers, Study Finds
NY Times
MedImmune goes after challenging lupus market
If your favorite TV shows go dark, health care costs might be to blame
Advisory Board Daily Briefing

4/26 ESRX After Anthem
Express Scripts Faces a Future Without Its Biggest Customer Express Scripts earned $10.24 for every prescription dispensed to people insured by Anthem, or nearly double what it made across all prescriptions .... WSJ

4/26 Lilly Reports Q1: Taltz, Trulicity Strong; Jardiance, Cyramza, and Basaglar Disappoint
Lilly Diabetes Drug Jardiance Falls Short Jardiance's first-quarter sales, at $74 million, were well below the $93.6 million average of analysts' estimates.... Two other new treatments, cancer drug Cyramza and diabetes treatment Basaglar, also came in lower than predicted .... Bloomberg (autoplay video)

4/26 Jimenez Thinks Early-Stage Acquisitions Are a Better Bet
Novartis Moves M&A Search to Early-Stage Drugs on Price Gain Novartis is counting on newer treatments such as heart drug Entresto, psoriasis treatment Cosentyx and Kisqali for breast cancer to help offset a decline in sales of blockbuster Gleevec .... Bloomberg (autoplay video)

4/26 Interview with Chief Digital Officer of GSK Consumer Healthcare
GSK's Speichert: Marketers Are Missing Digital Fundamentals Content is even more fragmented and the need for it greater than ever. How do you build the right ecosystem of suppliers? A lot of people are developing their own direct-to-consumer sites and trying to do it themselves .... Advertising Age

4/26 New Entries in MS Market Drive Deals; Biogen Offers Spectrum of Treatments
Biogen CEO eyes value-based payer deals to boost pressured MS franchise Biogen's MS franchises turned in $2.183 billion in first-quarter sales, a 3% jump over 2016's first-quarter haul of $2.114 billion. But with new competition, notably from Roche's Ocrevus, the biotech's management is working to get creative with payers .... Fierce Pharma

4/26 The Prospect of a New Administration Concentrates Pharma's Mind Wonderfully
Drugmakers Dramatically Boosted Lobbying Spending In Trump's First Quarter Trump has come down hard on drugmakers, stating in a press conference before his inauguration that the industry is "getting away with murder." He has promised to lower drug prices and increase competition with faster approvals and fewer regulations .... Kaiser Health News

4/26 Case Before Supremes Could Limit "Forum-Shopping"
U.S. Supreme Court may limit where companies can be sued Bristol-Myers was appealing a California Supreme Court ruling allowing that state's courts to hear claims related to its blood-thinning medication Plavix even though most plaintiffs do not live in the state and the company is not based there .... Reuters/Yahoo

4/26 Erenumab, For Migraine, to be Filed in Mid-2017
Novartis, Amgen Divvy Global Marketing of New Migraine Drug Erenumab is a fully human monoclonal antibody specifically designed for the prevention of migraine and targets and blocks the Calcitonin Gene-Related Peptide (CGRP) receptor.... Positive results from a Phase II study and two Phase III studies showed erenumab "significantly" reduced monthly migraine days versus placebo .... The Street

4/26 Internet Drug News Fast Takes:
Study: Medical-marijuana laws lower prescription drug usage
Teva Pharmaceutical CFO to Step Down
NY Times
JAMA Forum: Where Does the Health Insurance Premium Dollar Go?
by Uwe Reinhardt, Princeton University health care economist
Micro-Hospitals Provide Health Care Closer to Home
US News & World Report
AstraZeneca moving costs rise as new HQ nears completion
Republicans finalize new Obamacare repeal proposal

4/25 Anthem Drops Express Scripts; Claims Overcharging
Express Scripts expects to part ways with Anthem, its biggest client When Anthem leaves after 2019, Express Scripts will lose more than 20 million members, leaving it with about 65 million .... St. Louis Post Dispatch

4/25 Xarelto Faces 18,000 Lawsuits Claiming Harm
J&J, Bayer Accused of Hiding Blockbuster Blood Thinner's Dangers The companies are facing more than 18,000 U.S. patient suits blaming the blood thinner for internal bleeding. The medicine also has been linked to at least 370 deaths, according to FDA reports .... Bloomberg

4/25 Fresenius Buys Generics-Maker Akorn; Also Buys Merck KGaA Biosimilars
Fresenius to Buy Akorn for $4.3 Billion to Gain Generics The German company will pay about $34 a share for Akorn, according to a statement. Akorn, which had about $1 billion in sales last year, will complement the Kabi medicines unit .... Bloomberg

4/25 Gold Rush to Develop Drugs for (Non-Alcoholic) Fatty Liver
NASH: The Next Untapped Pharma Market Gives Investors Many Options Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020 .... NY Times

4/25 Maker of $750,000 Spinal Atrophy Drug Finds Support in Phase 3; About 100 Patients Treated So Far
Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers In new phase 3 data from a study in children with later-onset SMA, patients on Spinraza "demonstrated a highly statistically significant and clinically meaningful improvement in motor function" over their counterparts who received a sham treatment .... Fierce Pharma

4/25 Roche and Merck Lead in New R&D Spending
The top 15 spenders in the global drug R&D business: 2017 The top five in the business saw their collective spending jump by more than $5 billion, from 2015 to 2016, based on the annual numbers .... Endpoints

4/25 Endpoints Scoop: Marathon Closing Down
Marathon Pharmaceuticals signals it will wind down after stirring a hornet's nest with $89,000 Duchenne treatment Marathon Pharmaceuticals has been quietly discussing plans to shutter its operations after kicking up a storm of controversy over an effort to market a cheap overseas steroid to the Duchenne muscular dystrophy community .... Endpoints

4/25 Nuplazid Works for Three Fourths of Those Receiving; Half of Responders Improve Dramatically
New drug provides long-awaited breakthrough for Parkinson's psychosis Up to half of Parkinson's patients develop psychosis at some time during the disease's course, often in the later stages and sometimes as a side effect from drugs prescribed to help motor skills... Antipsychotic drugs used for schizophrenia don't help because they block dopamine in the brain, which also is what Parkinson's does .... Kansas City Star via Chicago Tribune

4/25 Mylan Sued Over Epinephrine Injector Tactics
Mylan Tried to 'Squelch' EpiPen Rival, Sanofi Says in Lawsuit Mylan executives offered 'unprecedented' price rebates to persuade government officials, insurance companies and pharmaceutical benefit managers not to reimburse patients for Sanofi's competing Auvi-Q allergy treatment .... Bloomberg

4/25 Breast Cancer Succeeds in Phase 3; Potential Competitor to Ibrance and Kisqali
Lilly's abemaciclib hits mark in MONARCH 3 Hitting the primary endpoint early puts abemaciclib on relatively equal ground with Ibrance, which was able to stop Pfizer's PALOMA-2 trial after interim analysis.... Where Lilly's drug loses an edge, however, is on safety — particularly diarrhea .... BioPharma Dive

4/25 Internet Drug News Fast Takes:
Nominee to head FDA joined effort to get a drug company more fentanyl
Washington Post
BioMarin sees 'high end' pricing on Brineura ahead of FDA decision: analyst
Fierce Pharma
PerfectLens sees ROI with programmatic ad buying
QuintilesIMS in Deal to Use's Cloud Technology
WSJ ($$)
Active ingredients in both hot peppers and cannabis calm the gut's immune system
Medical Xpress

4/24 Fast Takes
Biogen Says It's Back and Ready for 'Highly Active' Dealmaking
Yahoo Business
Trump Executive Order Could Revive Allergan-Pfizer Merger
The Street
EU Regulatory panel recommends nod for Sanofi, Regeneron's arthritis drug
10 Reasons Merck Could Be the World's Most Perfect Stock
Motley Fool
Novartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
Fox Business

4/24 FDA Clears Merck/Samsung Biosimilar Version Of Remicade (infliximab)
- Brand name = Renflexis
FDA Clears Second Remicade Biosimilar (Renflexis) … second FDA-approved biosimilar to the US-licensed reference product Remicade …  same indications as original infliximab. … Medscape]
See Also: RENFLEXIS package insert

Valproate Blamed For Thousands Of Birth Defects
- Launched by Sanofi in 1967; alleged victims seek money fron Sanofi
New evidence in France of harm from epilepsy drug valproate …  Mothers treated with valproate for epilepsy were up to four times likelier to give birth to a malformed child … risk of birth defects associated with valproate, marketed as Epilim, Depakine, Depakote and Stavzor among other names, has been known since the 1980s …[BBC]
See VIDEO: Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says … Regulators say that the defects were apparent in children whose mothers took the drug between 1967 and 2016 … [The Street]

Valeant Hopes Cheap Relatively Price For Siliq
(brodalumab) Will Drive Demand
- Will presence of black box affect payer acceptance?*
Black box warning? No worries, Valeant bills Siliq as the 'low-cost' psoriasis alternative to rivals from Novartis, Eli Lilly … now that it has the FDA's approval to sell the drug as Siliq, Valeant is aiming at a pair of major league rivals by pricing at a slightly lower list price … [Endpoints News]
Valeant's $3,500 sticker on Siliq could trigger a pricing war with Lilly, Novartis … Stelara, which ran about $7,661 per injection at the time, or about $46,000 for the initial year of therapy. At $3,500 per month, Siliq's annual cost would be $42,000 …[Fierce Pharma]
*Editor's Note:  Many common drugs such as birth control pills, GLP1 inhibitors, most antidepressants, etc., have black box warnings.  Black box warnings are not known to kill a drug's earning potential.

Teva Launches Advair Knockoff
Teva's new asthma inhaler poses first competition for GSK's Advair … AirDuo is not a true generic of Advair, but contains the same two active ingredients, fluticasone propionate and salmeterol. However, it delivers a lower dose of salmeterol and uses Teva's RespiClick inhaler rather than copying GSK's device … [Reuters]
See Also: AirDuo Package Insert

Dupixent (dupilumab): Amgen Sues Sanofi , Claims New Eczema Drug Infringes
Sanofi Genzyme hit with patent lawsuit over new eczema drug … subsidiary of Amgen  filed a complaint claiming that an eczema drug developed by Sanofi and Regeneron  infringes a patent related to a failed asthma treatment … [Boston B usiness Journal]

Good Riddance: Marathon Quits PhRMA:
Marathon Pharma is the latest drug maker to leave the industry trade group … Now that Marathon Pharmaceuticals has sold its Duchenne muscular dystrophy drug, the company unceremoniously withdrew from a big industry trade group, which began a review of its membership criteria two months ago after Marathon caused a stink over its pricing ;… [Pharmalot]

21st Century Patent Cliff Looms:
Viagra, Cialis, Humalog, Many Biotech Drugs At Risk
Big Pharma faces $26.5B in losses this year as next big patent cliff looms, analyst says … 45% of the sales at risk looking forward are for biologics … "erosion rates will be slower," but still "unpredictable." …[Fierce Pharma]
See Also: Top 10 U.S. patent losses of 2017 …[Fierce Pharma]

REPORT: FTC May Sue To Prevent Walgreen/Rite Aid Tie-Up
Rite Aid Falls on Report FTC May Sue to Block Walgreens Deal … timeline to complete the deal has been extended until July 31 as antitrust regulators review it … Walgreens Chief Executive Officer Stefano Pessina said he was "still optimistic" his company will get approval … [Bloomberg]

4/21 Pharma Pricing is a Rigged Game Says This Trial Lawyer; He's Suing Mylan and Insulin Makers
Meet the lawyer trying to pry drug pricing secrets out of Big Pharma Class-action attorney Steve Berman sees the drug pricing system as a Rube Goldberg machine for extracting money from patients: Pharma sets a high price for a given medication, and then promises a big, undisclosed rebate to the pharmacy benefit managers who control which drugs get covered by insurers .... Stat

4/21 Here's Your Weekend Reading
Magellan MRx Pipeline: A view into upcoming specialty and traditional drugs Includes 5-year projected total annual US sales through the year 2021 .... Magellan MRx (PDF)

4/21 Veliparib Misses in Lung Cancer and Breast Cancer
AbbVie's PARP inhibitor fails two late-stage cancer trials The primary endpoint of the NSCLC trial, which AbbVie's candidate failed to meet, was to improve overall survival compared to placebo for one subgroup of patients who had smoked within the last 12 months and at least 100 times in their lives .... Biopharma Dive

4/21 Who's Pocketing the Rebates? Not Us, Says Everyone
In the debate over rising drug prices, both drugmakers and PBMs claim innocence A study commissioned by the Pharmaceutical Care Management Association (the PBMs) says that 90 percent of the value of the rebates are passed along to companies that sponsor health plans and to consumers. Drug companies disagree .... CNBC (autoplay video)

4/21 Brand Maker Still Liable for Suicide by User of Generic; Even with Black Box
GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury The jury's award followed a trial in federal court in Chicago in a lawsuit over the death of Stewart Dolin, a partner at Reed Smith LLP who jumped in front of an oncoming commuter train in 2010 after taking a generic equivalent of GSK's Paxil .... Reuters

4/21 Wholesalers Getting Squeezed
Cardinal Health's Unhappy Profit Surprise: The Coevolution of Pharmacy Buying Groups and Wholesaler Economics Independent pharmacies — the most profitable customers of wholesalers — are successfully using their own buying groups to extract lower prices from wholesalers .... Drug Channels

4/21 Economists Suggest Drug Companies Buy "Trial Failure" Insurance
FDA Hedges: A Proposal to Better Share R&D Risks If a company is developing a new oncology drug that has made it to a Phase 2 clinical trial, the company could buy an option for $737,000, and if the treatment fails in the trial, the company would recoup $1 million (though if the treatment made it past Phase 2, the company would lose the $737,000) .... Regulatory Focus

4/21 Million Dollar Drug Will Go Off the Market; Only Ever Used on One Patient (It Worked)
With its launch fizzling out, UniQure gives up on $1M+ gene therapy Glybera The drugmaker says it won't ask European authorities to renew the $1-million-plus gene therapy's marketing authorization when it expires in October .... Fierce Pharma

4/21 Walgreens-Rite Aid Deal Looking Shaky
FTC reportedly may sue to block WBA-Rite Aid deal On Jan. 30, WBA and Rite Aid had extended the end date for the agreement to July 31, as well as lowered the purchase price and raised the number of stores that could be divested from up to 1,000 to as much as 1,200 .... Chain Drug Review

4/21 FDA Restricts Painkillers for Kids
FDA: Don't Give Kids Meds With Codeine, Tramadol Nursing mothers should also avoid using these drugs, since they can pass unsafe levels of opioids to their babies through their breast milk .... WebMD

4/21 Who Really Needs a Statin? — Depends Who You Ask
Differing Statin Guidelines Leave Many Clinicians Uncertain If all doctors followed the latest guidelines from the USPSTF for statin use, the number of Americans aged 40 to 75 on these medications would rise by 16 percent. If all doctors followed the advice of the American College of Cardiology/American Heart Association, statin use would increase by 24 percent. .... HealthDay News

4/21 Internet Drug News Fast Takes:
Teva launches copy of asthma inhaler Advair
The Cutting Edge Pharmacy / KTX archiLAB
(A Japanese pharmacy that could be an Apple store)
arch daily
What Country Spends The Most (And Least) On Health Care Per Person?
Upsher-Smith to sell generics business for $1.05B
Drug Store News
Sanofi says could buy device assets to boost diabetes

4/20 What is a 'Brand Penalty', And How Many Are Paying It?
Grassley probes insurer over 'penalties' charged for brand-name drugs Here's the scenario: A CareFirst beneficiary is prescribed a drug by a doctor, who purposely notes that only a brand-name drug should be dispensed. But when the patient pays at the pharmacy, they are charged the difference in cost between a brand-name and corresponding generic, instead of the expected co-pay which, invariably, would be lower. .... Stat/Pharmalot

4/20 Condé Discovered that 73% of Its Readers Don't Use Sites Like WebMD and Everyday Health — So It Made Its Own Vertical
New Condé Nast division aims to lure pharma with patient targeting, branded content To personalize content for particular types of patients, Condé Nast will use its proprietary data-optimization platform called Spire. Partnered with IMS for use in health and wellness, Spire will be able to target particular patients with specific advertising or custom content, based on each person's patient journey .... Fierce Pharma

4/20 Xarelto Down 10%; Invokana Down 17% Q1/Q1
J&J blames lower Xarelto and Invokana sales on payer pressure CFO Dominic Caruso told investors that heavy competition in cardiovascular and metabolic categories has given payers more leverage and, as a result, forced the drugmaker to offer higher rebates to maintain competitive positioning on formularies .... MM&M

4/20 Prosecutors in Generics Price-Fixing Case Following Trail Up the Ladder
The Billionaire And The Drug Price-Fixing Scandal Former Horizon CEO Jeffrey Glazer is cooperating with federal prosecutors -- and Satish Mehta, CEO of Indian parent company Emcure Pharmaceuticals, appears to be the next target in the politically charged war against price gouging .... Forbes/Nathan Vardi

4/20 Fujifilm Aims for $1 Billion in Biologics Manufacturing Business
Fujifilm Plans Bigger Global Push Into Complex Biologic Drugs Fujifilm plans to add three 2,000-liter tanks to manufacture antibodies in a recently completed plant in Texas.... The company is also expanding a U.K. facility to boost development of the production process of biologic products. .... Bloomberg

4/20 Hospira (Former Pfizer Unit) Part of Fed Probe into Saline Supply and Prices
Pfizer subpoenaed in U.S. intravenous saline solution probe The probe comes amid a shortage of intravenous saline solutions commonly used to hydrate hospital patients that dates back to late 2013....since the shortage began, prices have risen 200 percent to 300 percent .... Reuters

4/20 Zejula Price Announcement Clarified
UPDATED: Is Tesaro playing a pricing game with Zejula? Not at all, says the CEO. And here's why Most patients will not wind up at the recommended starting dose of 300 mg per day, says the CEO, who says that the majority of patients will be treated for far less than the top price .... Endpoints

4/20 This Wristband Will Make You Sweat — And That's a Good Thing
New in Wearable Health Tech: A Wrist Sensor That Works up a Sweat Researchers have put together sweat-stimulating compounds into a small device that delivers a low current. It can measure glucose, sodium and other compounds in the sweat and wirelessly relay that information .... NBC News

4/20 Breast Cancer Gene Tests Not Understood or Used
Do patients and doctors understand breast cancer genetic testing results? If you have early-stage breast cancer and have undergone genetic testing, the odds are high that the results were not explained to you by a genetic counselor, and chances are, the results did not affect your surgeon's recommendations for treatment .... Reuters

4/20 Cardinal Projects Generic Drug-Price Deflation for 2017 in Low Double Digits
Generic Drug Woes Aren't Going Away A multi-year price crunch in generic and specialty drugs may not be going anywhere soon -- just as the market for such assets appears to be getting hot .... Bloomberg Gadfly

4/20 Internet Drug News Fast Takes:
Vaping Venture Poses Potential Conflict for Trump's FDA Nominee
Alphabet's Verily unit launches study to track health data
FDA releases new treatment for cluster headaches
Introducing Solv: making it easy to get well soon
(Startup promises "same-day urgent care appointments without a wait")
Company posting
Abbott sees Alere as challenging 'fixer-upper' after revised deal

4/19 90+ Drugs Cost > $100,000 Per Year; Here Are the Very Most Costly
The 7 Most Expensive Prescription Drugs in the World The costs of these drugs are astronomical -- from $543,000 per year to more than $1 million per year .... Motley Fool

4/19 Need for Adherence Collides with Irrationality of Human Behavior; Many Heart Attack Survivors Won't Take Meds Even If They're Free
The Cost of Not Taking Your Medicine Lack of adherence is estimated to cause approximately 125,000 deaths and at least 10 percent of hospitalizations, and to cost the American health care system between $100 billion and $289 billion a year .... NY Times

4/19 CAR-T Results from JULIET Impress FDA; Rest of Us in the Dark
Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps Both Novartis and Kite have already submitted their respective CAR-T therapies to the FDA but the initial approval requests are for different types of blood cancer patients. Novartis' marketing package for CTL019 covers children with acute lymphoblastic leukemia (ALL.) Kite is going for approval of KTE-C19, also known as axi-cel, in diffuse large B-cell lymphoma .... The Street (autoplay video)

4/19 How Valeant Coopted the Wilsons Disease Association with a $100,000 Donation
How Drug-Company 'Benevolence' Silences the Sick Today, Valeant charges around $300,000 for a year's worth of Syprine (up from $1,460). The company's most recent annual report shows that the division that houses Syprine and many other controversial drugs generated $1.5 billion in profit in 2016, on 1.9 billion in revenue .... Bloomberg

4/19 Overview of J&J Q1; 6% Sales Drop vs. 2016
Pharma bellwether J&J not worried about drug pricing for specialty meds Weaker-than-expected performance from Stelara (ustekinumab), Zytiga (abiraterone acetate) and Xarelto (rivaroxaban) — all top brands for the drugmaker — weighed on pharmaceutical sales overall .... BioPharma Dive

4/19 Novartis Has 300+ Scientists in China; Market is Opening Up
Novartis Predicts Chinese Drug Market Growth Will Accelerate .... The Chinese pharmaceutical market may exceed $300 billion in sales by 2020, Chief Executive Officer Joe Jimenez said .... Bloomberg

4/19 Health Content Sites Built on Banners and Text Face Audience Shift to Mobile/Video
Some brands thought to shift online ad dollars, creating uncertainty for WebMD Advertisers, in general, are no longer spending as much banner ads, with Zenith reporting a 3.1% decline in banner-ad spending in 2016 .... MM&M

4/19 The Exec Who Brought You Provenge Now Back in the Game
Ex-Dendreon chief Mitch Gold steers his way back to the public markets, looking to jumpstart a new clinical program .... Alpine's top scientists — Ryan Swanson and Michael Kornacker, who both left Amgen after the big biotech opted to shutter its Seattle campus — have come up with some new tech that they believe can make CAR-Ts and TCRs better equipped to hunt down and destroy cancer cells .... Endpoints

4/19 420,000+ Americans on Dialysis; Avg. Annual Cost $88,000
Rethinking dialysis: Giving patients choices As more elderly people suffer kidney failure, new data reveal a troubling pattern for dialysis patients: A high percentage die anyway, and even those who live longer often don't live well. That has led some patients and doctors to consider disconnecting the dialysis machine .... Boston Globe

4/19 Trail of Duplicated (Non-original) Images Leads to Retracted Research
Former Pfizer Cancer Scientist Gets All 5 Papers Retracted "We have been able to confirm that all or nearly all of the images in these five articles that were flagged as potential duplicates on indeed appear to be duplicates." (Yvonne Cristovici, assistant general counsel in Compliance Division of Pfizer) .... Biospace

4/19 Internet Drug News Fast Takes:
Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records
(Quick summary: machine learning outperformed standard models to predict risk of heart attack)
Some vets can go to CVS 'MinuteClinics' for minor illnesses
Secret Data On Hospital Inspections May Soon Become Public
Propublica via NPR
Nonprofit Working To Block Drug Imports Has Ties To Pharma Lobby
NPR/Kaiser Health News
UnitedHealth plans for costly Obamacare tax in 2018
Allergan, Argentum settle patent dispute over eye drug Restasis

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 4/23/2017

If your intellectual property being infringe
e-mail the webmaster and we will fix it. 

The information on this site is not meant as medical advice.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

The information contained on this web site is for your information only.  Never take a drug without a doctor's prescription - only an idiot does that.   
Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

Do NOT start or stop taking a medicine based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!